vs
Side-by-side financial comparison of BioNTech SE (BNTX) and Molson Coors Beverage Company (TAP). Click either name above to swap in a different company.
Molson Coors Beverage Company is the larger business by last-quarter revenue ($2.7B vs $1.5B, roughly 1.8× BioNTech SE). Molson Coors Beverage Company runs the higher net margin — 5.5% vs -1.9%, a 7.4% gap on every dollar of revenue.
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Molson Coors Beverage Company is a Canadian-American multinational drink and brewing company headquartered in Chicago, Illinois and Montreal, Quebec.
BNTX vs TAP — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $2.7B |
| Net Profit | $-28.7M | $150.1M |
| Gross Margin | — | 33.0% |
| Operating Margin | -3.1% | — |
| Net Margin | -1.9% | 5.5% |
| Revenue YoY | — | 2.0% |
| Net Profit YoY | — | 25.0% |
| EPS (diluted) | — | $0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.7B | ||
| Q4 25 | — | $3.1B | ||
| Q3 25 | $1.5B | $3.5B | ||
| Q2 25 | $260.8M | $3.7B | ||
| Q1 25 | — | $2.7B | ||
| Q4 24 | — | $3.2B | ||
| Q3 24 | $1.2B | $3.6B | ||
| Q2 24 | — | $3.8B |
| Q1 26 | — | $150.1M | ||
| Q4 25 | — | $238.3M | ||
| Q3 25 | $-28.7M | $-2.9B | ||
| Q2 25 | $-386.6M | $428.7M | ||
| Q1 25 | — | $121.0M | ||
| Q4 24 | — | $287.8M | ||
| Q3 24 | $198.1M | $199.8M | ||
| Q2 24 | — | $427.0M |
| Q1 26 | — | 33.0% | ||
| Q4 25 | — | 31.0% | ||
| Q3 25 | — | 33.7% | ||
| Q2 25 | — | 34.3% | ||
| Q1 25 | — | 31.6% | ||
| Q4 24 | — | 32.0% | ||
| Q3 24 | — | 33.4% | ||
| Q2 24 | — | 34.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 10.4% | ||
| Q3 25 | -3.1% | -98.5% | ||
| Q2 25 | -192.1% | 15.6% | ||
| Q1 25 | — | 6.9% | ||
| Q4 24 | — | 12.0% | ||
| Q3 24 | 0.8% | 12.5% | ||
| Q2 24 | — | 15.6% |
| Q1 26 | — | 5.5% | ||
| Q4 25 | — | 7.6% | ||
| Q3 25 | -1.9% | -84.0% | ||
| Q2 25 | -148.2% | 11.5% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | 15.9% | 5.5% | ||
| Q2 24 | — | 11.1% |
| Q1 26 | — | $0.80 | ||
| Q4 25 | — | $1.32 | ||
| Q3 25 | — | $-14.79 | ||
| Q2 25 | — | $2.13 | ||
| Q1 25 | — | $0.59 | ||
| Q4 24 | — | $1.39 | ||
| Q3 24 | — | $0.96 | ||
| Q2 24 | — | $2.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $382.6M |
| Total DebtLower is stronger | — | $3.8B |
| Stockholders' EquityBook value | — | $10.3B |
| Total Assets | — | $22.4B |
| Debt / EquityLower = less leverage | — | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $382.6M | ||
| Q4 25 | — | $896.5M | ||
| Q3 25 | — | $950.2M | ||
| Q2 25 | — | $613.8M | ||
| Q1 25 | — | $412.7M | ||
| Q4 24 | — | $969.3M | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | — | $3.8B | ||
| Q4 25 | — | $6.3B | ||
| Q3 25 | — | $6.3B | ||
| Q2 25 | — | $6.3B | ||
| Q1 25 | — | $6.2B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.2B | ||
| Q2 24 | — | $7.0B |
| Q1 26 | — | $10.3B | ||
| Q4 25 | — | $10.2B | ||
| Q3 25 | — | $10.3B | ||
| Q2 25 | — | $13.4B | ||
| Q1 25 | — | $13.1B | ||
| Q4 24 | — | $13.1B | ||
| Q3 24 | — | $13.3B | ||
| Q2 24 | — | $13.2B |
| Q1 26 | — | $22.4B | ||
| Q4 25 | — | $22.7B | ||
| Q3 25 | — | $22.9B | ||
| Q2 25 | — | $26.8B | ||
| Q1 25 | — | $25.9B | ||
| Q4 24 | — | $26.1B | ||
| Q3 24 | — | $26.6B | ||
| Q2 24 | — | $27.4B |
| Q1 26 | — | 0.38× | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.61× | ||
| Q2 25 | — | 0.47× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
